Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms.

Front Immunol · 2025 · PMC12626996 · PMID 41268542

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0615

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Low-dose tofacitinib significantly extended survival of ALS mice compared to untreated control ALS mice in the intervention (6.2 day increase; p = 0.02) and cycle (7.3 day increase, p = 0.004) regimens and showed a trend towards improvement in the prevention regimen (p = 0.06; Figure 1B ).

also in 26,766 other papers

near-significantp = 0.0615so close (0.05 < p ≤ 0.1)

Power calculations and randomization Cohort sizes were determined by doubling cohort sizes from our previous study examining the role of NK cells in ALS, which found a near-significant (p = 0.0615) survival effect ( 7 ).

also in 1,356 other papers

did not reach statistical significanceno p-value reported

Interestingly, we found that high-dose tofacitinib increased cytokine expression in NK cells, though this effect did not reach statistical significance ( Supplementary Figure 6A ).

also in 59,377 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.